Key Highlights
- Foresite Capital promotes Drs. Hyung Chun and Cindy Xiong to partner roles.
- Chun and Xiong to lead investments across a broad range of therapeutic areas.
- $900M fund closed for continued investment in groundbreaking technologies.
- Significant impact made in autoimmune diseases, cellular therapies, and pain medications.
Source: Business Wire
Notable Quotes
- “Cindy and Hyung have demonstrated the ability to invest across both early and later stage opportunities working closely with entrepreneurs to build the next generation of healthcare companies.” — Jim Tananbaum, Founder and CEO at Foresite Capital
- “They have both made a substantial impact across the Foresite portfolio leading to investments in novel areas, including next generation treatments for autoimmune diseases, innovative cellular therapies and medications for acute and chronic pain.” — Michael Rome, Managing Director at Foresite Capital
- “It has been an amazing journey working with our outstanding investment team since joining Foresite nearly three years ago. I am eager to continue our mission to address critical unmet needs in healthcare and make transformative impacts on patients’ lives.” — Hyung Chun, Partner at Foresite Capital
SoHC's Take
The promotion of Drs. Hyung Chun and Cindy Xiong to partners at Foresite Capital underscores the firm’s commitment to fostering talent with a strong background in both scientific research and healthcare investment. Their extensive academic and professional backgrounds equip them well to identify and nurture groundbreaking technologies. This move not only strengthens Foresite’s leadership team but also positions the firm to continue making significant strides in addressing unmet medical needs through innovative therapeutic solutions. The closing of the $900M fund further amplifies Foresite Capital’s capacity to drive advancements in the biotech and life sciences sectors, ensuring sustained growth and impactful investments.
